We are live on
!
Find out more
AC
Ascend Capital Portfolio holdings
AUM
$1.99B
1-Year Est. Return
10.36%
This Fund
S&P 500
This Quarter
Est. Return
+10.76%
1 Year Est. Return
+10.36%
3 Year Est. Return
+56.79%
5 Year Est. Return
+86.43%
10 Year Est. Return
–
AUM
$3.28B
AUM Growth
+$597M
(+22%)
Cap. Flow
+$166M
Cap. Flow
% of AUM
5.04%
Top 10 Holdings %
Top 10 Hldgs %
22.55%
Holding
268
New
71
Increased
59
Reduced
39
Closed
90
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$77.8M |
| 2 |
Host Hotels & Resorts
HST
|
+$67.9M |
| 3 |
Wynn Resorts
WYNN
|
+$64.1M |
| 4 |
International Paper
IP
|
+$63.6M |
| 5 |
Advance Auto Parts
AAP
|
+$56.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$58.5M |
| 2 |
LVNTA
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
|
+$57.9M |
| 3 |
Travel + Leisure Co
TNL
|
+$56M |
| 4 |
ONIT
Onity Group
ONIT
|
+$44.1M |
| 5 |
Eagle Materials
EXP
|
+$42.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 18.75% |
| 2 | Healthcare | 13.67% |
| 3 | Technology | 10.55% |
| 4 | Financials | 10.48% |
| 5 | Materials | 10.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Brown-Forman Class B
BF.B
$12B
| $2.56M | 0.08% |
+105,938
| New | +$2.49M |
|
|
HZNP
152
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.52M | 0.08% |
+330,000
| New | +$1.78M |
|
|
NPSP
153
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $2.51M | 0.08% |
+82,587
| New | +$2.27M |
|
|
VAR
154
DELISTED
Varian Medical Systems, Inc.
VAR
| $2.25M | 0.07% |
33,000
-29,493
| -47% | -$1.96M |
|
|
NETI
155
DELISTED
Eneti Inc.
NETI
| $2.07M | 0.06% |
+1,844
| New | +$2M |
|
156
Vera Bradley
VRA
$105M
| $1.8M | 0.05% |
+75,000
| New | +$1.72M |
|
157
Green Plains
GPRE
$1.19B
| $1.77M | 0.05% |
91,401
-195,506
| -68% | -$3.23M |
|
|
MNTA
158
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $1.72M | 0.05% |
97,111
-146,888
| -60% | -$2.47M |
|
159
Pathward Financial
CASH
$1.81B
| $1.71M | 0.05% |
127,386
+5,391
| +4% | +$67.8K |
|
|
GEVA
160
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $1.67M | 0.05% |
25,809
+1,120
| +5% | +$66.5K |
|
161
Eastman Chemical
EMN
$7.8B
| $1.63M | 0.05% |
+20,205
| New | +$1.57M |
|
162
Jefferies Financial Group
JEF
$12.9B
| $1.45M | 0.04% |
+57,309
| New | +$1.45M |
|
163
Talphera
TLPH
$70.1M
| $1.39M | 0.04% |
6,139
-3,203
| -34% | -$557K |
|
|
AXLL
164
DELISTED
AXIALL CORP COM STK (DE)
AXLL
| $1.19M | 0.04% |
+25,000
| New | +$1.08M |
|
|
MGI
165
DELISTED
MoneyGram International, Inc. New
MGI
| $1.04M | 0.03% |
50,000
-62,581
| -56% | -$1.27M |
|
|
AMPE
166
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
| $784K | 0.02% |
+367
| New | +$868K |
|
167
Tenet Healthcare
THC
$20.1B
| $743K | 0.02% |
+17,620
| New | +$767K |
|
168
Integra LifeSciences
IART
$1.54B
| $443K | 0.01% |
+22,667
| New | +$416K |
|
|
AVNR
169
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
| $252K | 0.01% |
75,000
-904,370
| -92% | -$3.74M |
|
170
AbbVie
ABBV
$458B
| – | – |
-243,295
| Closed | -$10.9M |
|
171
Aegon
AEG
$13.5B
| – | – |
-683,911
| Closed | -$3.44M |
|
172
Amgen
AMGN
$203B
| – | – |
-121,508
| Closed | -$13.6M |
|
173
American Tower
AMT
$77.7B
| – | – |
-125,942
| Closed | -$9.34M |
|
174
Aon
AON
$77.3B
| – | – |
-17,733
| Closed | -$1.32M |
|
175
Amphenol
APH
$188B
| – | – |
-400,016
| Closed | -$3.87M |
|
Similar funds
MWAC
TP
PC
RW
TBC
BWCA
AC
GCM
Ascend Capital's Q4 2013 Portfolio in Review
As of Q4 2013, Ascend Capital held 268 positions worth $3.28B, up 22% from $2.69B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Ascend Capital deployed $166M of net new capital in Q4 2013, opening 71 new positions and adding to 59 existing holdings. Its largest new stake was Teva Pharmaceuticals: 1,975,045 shares worth $79.2M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 19% of assets, up from 14% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Liberty Interactive Corporation Series A Liberty Ventures, an estimated $57.9M trimmed.
- Ascend Capital's largest Q4 2013 buy was Teva Pharmaceuticals: 1,975,045 shares worth $79.2M.
- Ascend Capital added most to Host Hotels & Resorts in Q4 2013, an estimated $67.9M increase.
- Ascend Capital's biggest Q4 2013 reduction was Liberty Interactive Corporation Series A Liberty Ventures, cutting an estimated $57.9M.
- Ascend Capital fully exited Perrigo in Q4 2013, selling an estimated $58.5M.
- Ascend Capital's ten largest holdings make up 23% of its $3.28B portfolio in Q4 2013.
- Ascend Capital opened 71 new positions and closed 90 in Q4 2013.
- Ascend Capital's portfolio value rose 22% quarter-over-quarter to $3.28B.
Based on Ascend Capital's 13F filing for Q4 2013, filed 14 Feb 2014.